Brazil's Attorney General has reported that parts of the country's Industrial Property Law could be unconstitutional, if complaints by civil society groups are upheld. Articles 230 and 231 of Brazil's 9.297/96 legislation created a mechanism known as the pipeline, allowing drug patents to be approved, based on the date of first filing in a foreign country.
Critics note that, under some circumstances, the law means items that have entered the public domain are retrospectively attributed marketing exclusivity, according to Intellectual Property Watch. Pipeline patents in all sectors, including pharmaceuticals, accounted for 1,182 patent requests in Brazil, with 45% coming from US sources, Lia Hasenclever, a researcher at the Federal University of Rio de Janeiro, claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze